Akeso received clinical trial clearance from China’s NMPA for AK-157D1, enabling initiation of a Phase I study in patients with advanced solid tumors. The clearance allows the company to progress an early clinical assessment of the candidate’s safety and initial activity. The news adds to China’s continuing throughput in solid tumor pipeline development, with regulators repeatedly moving cleared assets into first-in-human settings. For developers, Phase I starts also signal near-term opportunities to establish dose-finding strategy and early pharmacodynamic readouts. As the study begins, market attention will likely focus on target biology, mechanism differentiation, and any early signs of response in defined tumor subtypes.